VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+26.97%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$922M
AUM Growth
+$922M
(+36%)
Cap. Flow
+$293M
Cap. Flow
% of AUM
31.79%
Top 10 Holdings %
Top 10 Hldgs %
73.15%
Holding
32
New
7
Increased
7
Reduced
5
Closed
4
Top Buys
| 1 |
Instil Bio
TIL
|
$172M |
| 2 |
Cullinan Oncology
CGEM
|
$49M |
| 3 |
Aclaris Therapeutics
ACRS
|
$44.5M |
| 4 |
Pharvaris
PHVS
|
$25.3M |
| 5 |
ESSA Pharma
EPIX
|
$18.2M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$18.5M |
| 2 |
Altimmune
ALT
|
$14.1M |
| 3 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$13.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$11.7M |
| 5 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
$9.39M |
Sector Composition
| 1 | Healthcare | 89.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ARS Pharmaceuticals
SPRY
$1.08B
| $3.71M | 0.4% |
85,000
-65,000
| -43% | -$2.84M |
|
27
Taysha Gene Therapies
TSHA
$791M
| $2.45M | 0.27% |
120,649
+12,667
| +12% | +$257K |
|
28
Viridian Therapeutics
VRDN
$1.59B
| $326K | 0.04% |
19,495
| – | – |
|
|
FPRX
29
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-245,122
| Closed | -$4.17M |
|
|
SURF
30
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-1,442,895
| Closed | -$13.3M |
|
31
BioAtla
BCAB
$28.7M
| – | – |
-100,000
| Closed | -$3.4M |
|
|
GRTX
32
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| – | – |
-917,860
| Closed | -$9.39M |
|